Vinorelbine
Top View
- Dose Escalation of Oral Vinorelbine in Combination with Estramustine in Hormone-Refractory Adenocarcinoma of the Prostate
- (MVD) in the Treatment of Metastatic Hormonoresistant Prostate Cancer — a Phase II Trial
- Package Leaflet: Information for the User
- Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
- Emetogenic Potential of Antineoplastic Agents
- LUNG CANCER TREATMENT REGIMENS (Part 1 of 7) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Handling Cytostatic Drugs: Contents
- Sequential Docetaxel Followed by Epirubicin-Vinorelbine As First-Line Chemotherapy in Advanced Breast Cancer
- TAXOTERE: TAXOTERE Safely and Effectively
- Low Dose of Arsenic Trioxide Inhibits Multidrug Resistant-Related P-Glycoprotein Expression in Human Neuroblastoma Cell Line
- Vinorelbine and Continuous Low-Dose Cyclophosphamide As Maintenance
- An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
- Vinorelbine and 5-Fluorouracil Bolus And/Or Continuous Venous Infusion Plus Levofolinic Acid As Second-Line Chemotherapy For
- Efficacy and Toxicity of Different Chemotherapy Protocols For
- First-Line Chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) Combination in Advanced Breast Cancer
- Guidelines for the Use of Anti-Emetics with Chemotherapy
- Shortages and Price Variability of Essential Cytotoxic Medicines for Treating Children with Cancers
- Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products